Stable biological and operational performance drove a 1,427-ton Q3 harvest, with 95% of sales at premium prices and a 19% price premium. Cost optimization and a $35m convertible loan support the path to EBITDA positive and Phase 2 expansion by end-2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.